Diakonos’ DC Vaccine Improves Survival in Phase 1 Glioblastoma Trial


Diakonos Oncology’s unique dendritic cell vaccine, DOC1021, has shown promising results in a Phase 1 trial for glioblastoma (GBM). The trial data, presented at the 2024 American Association for Cancer Research annual meeting on April 8, revealed that 12 out of 16 newly diagnosed GBM patients remained alive with no attributable serious adverse events at an average of 12.9 months of follow-up.

The current 12-month overall survival rate for unmethylated GBM patients treated with DOC1021 is 88%, which compares favorably to the historical 12-month survival rate of 53% for unmethylated GBM patients treated with standard of care. These results highlight the potential of DOC1021 as a novel and effective treatment option for GBM patients.

Based on the encouraging Phase 1 trial results, Diakonos Oncology plans to initiate a Phase 2 trial of DOC1021 to further evaluate its efficacy and safety in treating glioblastoma. The company remains committed to advancing innovative cancer therapies that can improve patient outcomes and quality of life.